|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅱ study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin' s lymphoma 显示文摘 | Vose JM Link BK Grossbard ML | 2001 | J Clin Oncol2001，19，2： | 1 |
| 2 | Primary sys-temic therapy of breast cancer显示文摘 | Sachelarie I Grossbard ML Chadha M el a1 | 2006 | Oncologist2006，，6： | 1 |
| 3 | Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care 显示文摘 | el-Kamar FG Grossbard ML Kozuch PS | 2003 | Oncologist2003，8，1： | 1 |
| 4 | Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care显示文摘 | el Kamar FG Grossbard ML Kozuch PS | 2003 | Oncologist2003，8，1： | 1 |
| 5 | Primary Systemic Therapy of Breast Cancer 显示文摘 | I Sachelarie ML Grossbard M Chadha | 2006 | Oncologist2006，11，6： | 1 |
| 6 | A phase Ⅰ study of gemcitabine and docetaxel in patients with metastatic solid tumors显示文摘 | Ryan DP Lynch TJ Grossbard ML | 2000 | Cancer2000，88，： | 1 |
| 7 | Phase II study of ritux-imab in combination with CHOP chemotherapy in patients with pre-viously untreated,aggressive non Hodgkin lymphoma(NHL)显示文摘 | Vose JM Link BK Grossbard ML | 2001 | J Clin Oncol2001，19，： | 1 |
| 8 | Irinotecan com- bined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer 显示文摘 | Kozuch P Grossbard ML Barzdins A | 2001 | On- cologist2001，6，6： | 1 |
| 9 | Primary systemic therapy of breast cancer 显示文摘 | Sachelarie I Grossbard ML Chadha M | 2006 | Oncologist2006，11，6： | 1 |
| 10 | Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma显示文摘 | Vose JM Link BK Grossbard ML | | 0，，： | 1 |
| 11 | Primary systemic therapy of breast cancer显示文摘 | Sachelarie L Grossbard ML Chadha M | 2006 | Oncologist2006，11，6： | 1 |
| 12 | Irinotecan combined with gemcitabine,5-fluorouracil,leucovorin,and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer显示文摘 | Kozuch P Grossbard ML Barzdins A | 2001 | Oncologist2001，6，： | 1 |
| 13 | PhaseⅡstudy of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma显示文摘 | Vose JM Link BK Grossbard ML | 2001 | J Clin Oncol2001，19，： | 1 |
| 14 | Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma显示文摘 | VOSE JM LINK BK GROSSBARD ML | 2001 | J Clin Oncol2001，19，2： | 1 |
| 15 | Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma 显示文摘 | Vose JM Link BK Grossbard ML | 2001 | J Clin Oncol2001，19，2： | 1 |
| 16 | Adjuvanttherapy of stage Ⅲ and Ⅳ malignant melanoma using granulocyte￣marcophage colony￣stimulating factor 显示文摘 | Grossbard ML Ernstoff MS | 2000 | JCO2000，18，： | 1 |
| 17 | Metastatic pan-creatic cancer: emerging strategies in chemotherapy andpalliative care显示文摘 | el-Kamar FG Grossbard ML Kozuch PS | 2003 | Oncologist2003，8，1： | 1 |
| 18 | Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin' s lymphoma 显示文摘 | Vose JM Link BK Grossbard ML | 2001 | J Clin Oncol2001，19，2： | 1 |
| 19 | Treat of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens显示文摘 | Treon SP ShimaY Grossbard ML etal | 2000 | Annal Oncol2000，11，1： | 1 |
| 20 | Phase Ⅱ study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma 显示文摘 | Vose JM Link BK Grossbard ML | 2001 | J Clin Oncol2001，19，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员